Stocks · News reference

Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial

Oct 1, 2026, 6:31 PMVandana Singh

Agomab Therapeutics reports positive 48-week Phase 2a trial data for ontunisertib in patients with fibrostenotic Crohn's disease.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Oct 1, 2026, 6:31 PM
Checked: Oct 1, 2026, 6:31 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 1, 2026, 10:38 AMBenzinga Newsdesk
Agomab Therapeutics Announces Results From 48-Week OLE Portion Of Its Phase 2A STENOVA Trial Evaluating Ontunisertib In Patients With Severe Crohn's Disease; Favorable Safety And Tolerability Profile Maintained Through Up To 60 Weeks Of Treatment; Low Annualized FSCD-Related Event Rate Of 3%
AGMB
BenzingaSep 14, 2026, 8:08 PMBenzinga Newsdesk
Agomab Says Phase 1 Data In 10 IPF Patients Show Favorable Safety, Target Engagement For Inhaled AGMB-447; Submits CTA For 120-Patient Phase 2 INSPIRIA Study, Targets Start In H2 2026
AGMB
BenzingaAug 25, 2026, 4:27 PMBenzinga Newsdesk
AgomAb Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a $60 price target.
AGMB